APRINOIA Therapeutics Inc. Launches a New Contract Service to Measure High-Molecular-Weight Oligomer Tau Species Using High-Sensitive ELISA System
APRINOIA Therapeutics Inc. Launches a New Contract Service to Measure High-Molecular-Weight Oligomer Tau Species Using High-Sensitive ELISA System Tokyo, Japan, May 7, 2025 – APRINOIA Therapeutics Inc. (“APRINOIA”), a clinical-stage biopharmaceutical company, is pleased to announce a new service for HMWoTau measurements for research institutions and companies engaged in pathophysiological research and drug/diagnostics development targeting […]
APRINOIA Therapeutics Reported a Novel Oligomer Tau Assay System with APNmAb005 Antibody, Successfully Detected the Target Molecule of Oligomer Tau Species and Elucidated the Increases Depending on Disease Progression of Alzheimer’s Disease
APRINOIA Therapeutics Reported a Novel Oligomer Tau Assay System with APNmAb005 Antibody, Successfully Detected the Target Molecule of Oligomer Tau Species and Elucidated the Increases Depending on Disease Progression of Alzheimer’s Disease Tokyo, Japan – December 10, 2024 – APRINOIA Therapeutics has developed a novel enzyme-linked immunosorbent assay (ELISA) that employs its proprietary monoclonal antibody APNmAb005, which […]
APRINOIA Therapeutics Announces Fast Track Designation Granted by U.S. FDA to APN-1607 for the Diagnosis of Progressive Supranuclear Palsy
APRINOIA Therapeutics Announces Fast Track Designation Granted by U.S. FDA to APN-1607 for the Diagnosis of Progressive Supranuclear Palsy Fast Track Designation follows announcement in January 2024 that the U.S. Food and Drug Administration (FDA) granted a “Study May Proceed” letter for APRINOIA’s planned Phase 3 study of APN-1607 (florzolotau (18F)) in the U.S.,U.K., Europe […]
APRINOIA Therapeutics Inc. receives “Study May Proceed” letter from FDA for a Phase 3 study of APN-1607 (florzolotau) for the diagnosis of Progressive Supranuclear Palsy
APRINOIA Therapeutics Inc. receives “Study May Proceed” letter from FDA for a Phase 3 study of APN-1607 (florzolotau) for the diagnosis of Progressive Supranuclear Palsy Cambridge, MA, January 3, 2024 — APRINOIA Therapeutics Inc. (“APRINOIA” or the “Company”) is pleased to announce that on December 8, 2023, the United States Food and Drug Administration (“FDA”) […]
APRINOIA Therapeutics Announces Strategic Investment From the Alzheimer’s Drug Discovery Foundation (ADDF)
APRINOIA Therapeutics Announces Strategic Investment From the Alzheimer’s Drug Discovery Foundation (ADDF) CAMBRIDGE, Mass., September 11, 2023 — APRINOIA Therapeutics (“APRINOIA” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics and precision diagnostics for the treatment of neurodegenerative diseases, headquartered in Cambridge, MA, is pleased to announce the strategic investment by the Alzheimer’s Drug […]
APRINOIA Therapeutics Appoints Mark S. Shearman, Ph.D., as Chief Executive Officer
APRINOIA Therapeutics Appoints Mark S. Shearman, Ph.D., as Chief Executive Officer Dr. Shearman, a pharma and biotech industry executive with an extensive track record of achievements in drug discovery and development, will lead the strategy and execution of the company’s clinical therapeutic and diagnostic programs August 28, 2023 11:00 ET APRINOIA Therapeutics (“APRINOIA”), a global […]
APRINOIA Therapeutics Announces Mutual Termination of Business Combination Agreement with ROSS Acquisition Corp II
APRINOIA Therapeutics Announces Mutual Termination of Business Combination Agreement with ROSS Acquisition Corp II CAMBRIDGE, Mass., Aug. 23, 2023 (GLOBE NEWSWIRE) — APRINOIA Therapeutics (“APRINOIA”), a global clinical-stage biopharmaceutical company developing novel therapeutics and precision diagnostics for the treatment of neurodegenerative diseases such as Alzheimer’s Disease (“AD”) and Progressive Supranuclear Palsy (“PSP”), announced a mutual […]
APRINOIA Therapeutics and ROSS Acquisition Corp II Announce Business Combination Agreement to Create Publicly Listed Company Focused on Neurodegenerative Diseases
APRINOIA Therapeutics and ROSS Acquisition Corp II Announce Business Combination Agreement to Create Publicly Listed Company Focused on Neurodegenerative Diseases ROSS SPAC will issue $280 million of stock for APRINOIA Therapeutics Precision Neurology Company Focused on Developing a Pipeline of Highly Specific Central Nervous System (“CNS”) Diagnostics and Therapeutics, including CNS Protein Degraders Anticipated Proceeds […]
APRINOIA Therapeutics received FDA clearance to initiate APNmAb005 Phase 1 clinical trial
APRINOIA Therapeutics received FDA clearance to initiate APNmAb005 Phase 1 clinical trial BOSTON, April 11, 2022 — APRINOIA Therapeutics announces today that the U.S. Food and Drug Administration (FDA) has granted a may proceed authorization for its novel therapeutic anti-tau monoclonal antibody, APNmAb005, allowing the company to test and evaluate its safety in healthy subjects in a […]
Insilico partners with APRINOIA on AI-powered neurodegenerative drug discovery
Insilico Medicine is pleased to announce that it has entered into a research collaboration with APRINOIA Therapeutics to utilize Insilico’s novel generative artificial intelligence (AI) technology to accelerate the discovery of next generation compounds targeting abnormal proteins in brain associated with neurodegenerative diseases.